^
Association details:
| Biomarker: | H3.3K27M |
|---|---|
| Cancer: | Glioma |
| Drug Class: | Hypomethylating agent |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The mutated chromatin modifier gene, H3F3AK27M, is a druggable target of DNA hypomethylating agents in pediatric high-grade glioma
Excerpt:
The prolonged antitumor effects in pHGG cells with H3K27M mutation observed after HMA treatment may be due to the failure of DNA remethylation and upregulated innate immune response pathway genes due to ERV reactivation....HMA treatment may be effective against pHGGs with the H3K27M mutation.
